Several class-action lawsuits have been filed against Abbott related to the formulas. According to the FDA, five environmental subsamples collected from Abbott's Sturgis, Mich., plant were positive for cronobacter sakazakii, but product samples collected were found to be negative for the bacteria. "Importantly, the FDA and the CDC found there is no genetic match between the strains of the bacteria identified in non-product contact areas of our facility and available samples attained from customer complaints, suggesting a different source of contamination," Abbott CEO Robert Ford said in an earnings call Wednesday. "We hope these findings give parents, caregivers and other stakeholders renewed confidence in our products." Abbott said it is working to resume operations at the Sturgis facility, implementing corrective actions and enhancements to the plant. Overall, lower Abbott's pediatric nutrition sales impacted performance in the company's nutrition products segment broadly.